Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir

Yu Bai; Fei Ye; Yong Feng; Hanyi Liao; Hao Song; Jianxun Qi; George Fu Gao; Wenjie Tan; Lifeng Fu; Yi Shi

doi:10.1038/s41392-021-00468-9

Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir

Signal Transduct Target Ther. 2021 Feb 4;6(1):51. doi: 10.1038/s41392-021-00468-9.

Authors

Yu Bai^#^{1

2}, Fei Ye^#³, Yong Feng^#^{1

2}, Hanyi Liao^{1

2}, Hao Song⁴, Jianxun Qi^{1

2}, George Fu Gao^{1

2

5}, Wenjie Tan⁶, Lifeng Fu^{7

8}, Yi Shi^{9

10

11}

Affiliations

¹ Savaid Medical School, University of Chinese Academy of Sciences, Beijing, 100049, China.
² CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China.
³ NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control & Prevention, Chinese Center for Disease Control and Prevention, China CDC, Beijing, 102206, China.
⁴ Research Network of Immunity and Health (RNIH), Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing, 100101, China.
⁵ Center for Influenza Research and Early Warning (CASCIRE), CAS-TWAS Center of Excellence for Emerging Infectious Disease (CEEID), Chinese Academy of Sciences, Beijing, 100101, China.
⁶ Research Network of Immunity and Health (RNIH), Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing, 100101, China. [email protected].
⁷ CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China. [email protected].
⁸ Center for Influenza Research and Early Warning (CASCIRE), CAS-TWAS Center of Excellence for Emerging Infectious Disease (CEEID), Chinese Academy of Sciences, Beijing, 100101, China. [email protected].
⁹ Savaid Medical School, University of Chinese Academy of Sciences, Beijing, 100049, China. [email protected].
¹⁰ CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China. [email protected].
¹¹ Center for Influenza Research and Early Warning (CASCIRE), CAS-TWAS Center of Excellence for Emerging Infectious Disease (CEEID), Chinese Academy of Sciences, Beijing, 100101, China. [email protected].

^# Contributed equally.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

COVID-19 / enzymology*
COVID-19 Drug Treatment
Coronavirus 3C Proteases* / antagonists & inhibitors
Coronavirus 3C Proteases* / chemistry
Cyclopropanes / chemistry*
Cyclopropanes / pharmacology
Cysteine Proteinase Inhibitors / chemistry*
Cysteine Proteinase Inhibitors / pharmacology
Hepacivirus / enzymology
Humans
Leucine / analogs & derivatives*
Leucine / chemistry
Leucine / pharmacology
Proline / analogs & derivatives*
Proline / chemistry
Proline / pharmacology
SARS-CoV-2 / enzymology*
Sulfones / chemistry*
Sulfones / pharmacology
Urea / chemistry*
Urea / pharmacology

Substances

Cyclopropanes
Cysteine Proteinase Inhibitors
Sulfones
narlaprevir
Urea
Proline
Coronavirus 3C Proteases
Leucine

Grants and funding

XDB29010000/Chinese Academy of Sciences Key Project (CAS Key Project)